Author | Morgan Petronelli


Weekly Roundup: September 21-25

September 25, 2020

ICYMI, some of the content featured this week includes articles about how to choose a telemedicine vendor, the launch of an international COVID-19 dermatology registry, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, plus more.

AAD, NPF guidelines urge liver disease monitoring in psoriasis patients

September 25, 2020

The latest guidelines for psoriasis from the American Academy of Dermatology and the National Psoriasis Foundation recommend physicians monitor their patients for liver disease when prescribed medication for psoriasis, such as methotrexate.

Picosecond laser evaluated in melasma study

September 24, 2020

A study published by the American Society of Laser Medicine and Surgery reveals the efficacy of the 755-nm picosecond laser as a treatment for melasma in Asian women with darker skin types.

Cross-specialty collaboration key to tracking COVID-19 skin symptoms

September 24, 2020

Esther Freeman, M.D., details the team effort made by the American Academy of Dermatology’s (AAD) COVID-19 Task Force to launch an international registry documenting skin manifestations in patients diagnosed with or suspected of COVID-19 infection.

Identifying dermatologic conditions in pediatric patients with COVID-19

September 23, 2020

A recent article suggests physicians should be on the lookout for various dermatologic manifestations in pediatric patients suspected of having COVID-19.

First patient enrolled in vitiligo repigmentation study

September 23, 2020

AVITA Therapeutics has launched a study evaluating their RECELL System as a treatment for stable vitiligo.

How to choose a telemedicine vendor

September 22, 2020

With the increase in telemedicine use, physicians can (virtually) meet their patients’ needs now more than ever. However, with this swift increase in telehealth usage, how can physicians choose the best telemedicine vendor for their practice with so many options available?

FDA, EMA accepts marketing applications for bimekizumab in psoriasis

September 22, 2020

UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.

The Mainstream Patient: September 21

September 21, 2020

This week’s edition of The Mainstream Patient features stories about dark circles, sun damage on different skin tones, wearing sunscreen with a mask, sleep’s effect on skin health, plus more.

Weekly Roundup: September 14-18

September 18, 2020

ICYMI, some of the content featured this week includes articles about a new diversity and equity initiative from Skinbetter Science and Allergan Aesthetics, patient sunscreen savviness, skin of color patients lacking in phase 3 psoriasis trials, plus more.